Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Grosse Pointe Dermatology Associates, P.C.
GROSSE POINTE, Mich., Oct. 25, 2013 /PRNewswire/ -- Board certified cosmetic Dermatologist, Dr. David Balle, of Grosse Pointe Dermatology Associates, P.C., has been chosen by Allergan, maker of the October 23, 2013 FDA approved Juvederm Voluma™ XC, to be the first physician in Michigan and amongst the first in the United States to inject Voluma in patients to treat volume loss in the mid-face.
Allergan has entrusted Dr. Balle, to be the first to use their latest facial filler because of his vast knowledge and experience in non-surgical facial rejuvenation and his artistic eye and techniques. In fact, Allergan has asked and employed Dr. Balle to be a physician injector trainer for years to teach other physicians nationally in the proper and safest injection techniques to achieve optimal aesthetic results for all of their cosmetic products including Botox, Juvederm XC, and Latisse. In addition, Dr. David Balle is a cosmetic physician injector trainer for Medicis for their products: SculptraAesthetic, Restylane, Perlane, and Dysport.
"As people age, the cheek area loses volume, making the cheeks flatten out and sink, causing the skin to droop and sag," said Dr. David S. Balle. Juvederm Voluma™ XC was recently approved by the FDA and is the first and only filler approved to temporarily correct age-related volume loss in the cheek in adults age 21 and older. It instantly provides smooth, natural-looking results that last up to two years with optimal correction. Juvederm Voluma™ XC is made with Allergan's proprietary VYCROSS™ technology, an advanced manufacturing process that results in smooth gel that flows easily and consistently. This unique formulation contributes to the life capacity to correct volume loss in the cheek area and to the duration of the product. Additionally, Juvederm Voluma™ XC contains a small amount of lidocaine which helps to numb the treatment area during the injection procedure.
"Now with Juvederm Voluma™ XC, I am excited to have a new treatment that can instantly help to life and pull back the cheek as it corrects age related volume loss with little or no downtime," said Dr. Balle. With the FDA approval of Juvederm Voluma™ XC, physicians and patients in the U.S. now have a new treatment option that can help create a natural-looking, more youthful appearance in the cheek area.
Dr. Balle would welcome the opportunity to discuss why and how the face loses volume as people age. He can also speak about how Juvederm Voluma™ XC is an effective non-surgical treatment option for age-related volume loss in the cheek area.
©2012 PR Newswire. All Rights Reserved.